Immunovant (IMVT) Accounts Payables (2019 - 2026)

Immunovant has reported Accounts Payables for 8 years, with the latest figure at $7.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 57.29% year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2026 stood at $7.5 million (down 57.29% YoY), and the FY2026 full-year result was $7.5 million, down 57.29% from the prior year.
• Accounts Payables for Q1 2026 stood at $7.5 million, down from $8.6 million in the prior quarter.
• The five-year high for Accounts Payables was $26.5 million in Q2 2023, with the low at $1.1 million in Q2 2022.
• Historically, Accounts Payables has averaged $11.0 million across 5 years, with a median of $7.8 million in 2025.
• The largest YoY upside for Accounts Payables was 2382.08% in 2023 against a maximum downside of 92.74% in 2023.
• Immunovant's Accounts Payables stood at $14.0 million in 2022, then plunged by 72.08% to $3.9 million in 2023, then surged by 406.8% to $19.8 million in 2024, then sank by 56.52% to $8.6 million in 2025, then decreased by 12.48% to $7.5 million in 2026.
• The last three Accounts Payables figures came in at $7.5 million (Q1 2026), $8.6 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.